암 진단용 인공지능(AI) 시장 : 산업 규모, 점유율, 동향, 기회, 예측 - 기술별, 암 유형별, 최종 사용자별, 지역별, 경쟁별(2020-2030년)

The Global Artificial Intelligence in Cancer Diagnostics Market was valued at USD 128.47 million in 2024 and is projected to grow significantly, reaching USD 208.62 million by 2030 with a CAGR of 8.54% during the forecast period. AI is transforming cancer diagnostics by enabling faster, more accurate detection of malignancies through the analysis of complex medical data such as imaging scans and genomic profiles. As cancer incidence rises globally, the demand for early detection tools that enhance clinical outcomes is accelerating. AI-powered diagnostic platforms can identify subtle patterns in data that might elude traditional methods, improving accuracy while reducing diagnostic time and human error. This has proven particularly valuable for high-burden cancers like breast, lung, and colorectal cancer. Technological advancements, increasing cancer prevalence, and a strong push for precision medicine are key factors driving market expansion. Moreover, successful applications such as DELFI's AI blood test for liver cancer highlight the potential of AI to improve early-stage diagnosis and long-term survival.

Key Market Drivers

Rising Cancer Incidence and Demand for Early Detection is Driving the Global Artificial Intelligence In Cancer Diagnostics Market

With cancer remaining a leading cause of death globally, early detection has become a top priority in healthcare systems. The growing incidence of cancer-attributed to aging populations, lifestyle factors, and environmental exposure-is driving demand for diagnostic tools that can catch tumors at their earliest and most treatable stages. AI is emerging as a game-changing technology in this regard. By analyzing extensive patient data, including radiologic and pathologic images, AI systems help clinicians identify malignancies faster and more accurately. For example, the American Cancer Society estimates over 2 million new cancer cases in the U.S. alone for 2024, underscoring the urgency for efficient diagnostic solutions. AI's ability to support rapid analysis and generate diagnostic insights across multiple cancer types enhances its value proposition, especially as healthcare providers seek scalable tools to meet increasing patient volumes and complexity in diagnostics.

Key Market Challenges

Data Quality and Quantity Poses a Significant Obstacle To Market Expansion

AI models require large, high-quality datasets to perform accurately and generalize effectively across populations. However, in cancer diagnostics, data availability and standardization remain significant hurdles. Variations in imaging protocols, inconsistent data labeling, and fragmented electronic health records can affect model training and limit diagnostic precision. Additionally, privacy concerns and regulatory barriers often restrict data sharing between institutions, limiting access to comprehensive datasets. These challenges slow the development of robust AI solutions and delay their clinical validation and deployment. Addressing this issue requires cross-institutional collaboration, anonymized data sharing frameworks, and rigorous data governance policies.

Key Market Trends

Technological Advancements

AI continues to advance rapidly, especially in areas such as machine learning, computer vision, and natural language processing. In cancer diagnostics, these technologies are enhancing image analysis, pathology workflows, and genomic profiling. AI algorithms now assist in detecting abnormalities in imaging scans with high precision, identifying early-stage tumors, and predicting treatment responses based on patient-specific genetic information. For instance, AI tools can detect textural or morphological changes in tissues that indicate early malignancies, which may not be visible to the human eye. Additionally, AI supports precision oncology by analyzing genomic mutations to match patients with targeted therapies. These technological innovations are improving diagnostic accuracy, reducing diagnostic delays, and enabling personalized treatment planning. As integration with clinical systems becomes more seamless, AI adoption in oncology diagnostics is expected to scale rapidly across healthcare institutions globally.

Key Market Players

• Medial EarlySign
• Cancer Center.ai
• Microsoft Corporation
• Flatiron Health
• Path AI
• Therapixel
• Tempus Labs, Inc.
• Paige AI, Inc.
• Kheiron Medical Technologies Limited
• SkinVision

Report Scope:

In this report, the Global Artificial Intelligence In Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Artificial Intelligence In Cancer Diagnostics Market, By Technology:

• Software Solutions
• Hardware
• Services

Artificial Intelligence In Cancer Diagnostics Market, By Cancer Type:

• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Colorectal Cancer
• Brain Tumor
• Others

Artificial Intelligence In Cancer Diagnostics Market, By End User:

• Hospital
• Surgical Centres and Medical Institutes
• Others

Artificial Intelligence In Cancer Diagnostics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Artificial Intelligence In Cancer Diagnostics Market.

Available Customizations:

Global Artificial Intelligence In Cancer Diagnostics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

4. Global Artificial Intelligence In Cancer Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Software Solutions, Hardware, Services)
  • 5.2.2. By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others)
  • 5.2.3. By End-User (Hospital, Surgical Centers and Medical Institutes, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Artificial Intelligence In Cancer Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Cancer Type
  • 6.2.3. By End-User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Cancer Type
      • 6.3.1.2.3. By End-User
  • 6.3.2. Canada Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Cancer Type
      • 6.3.2.2.3. By End-User
  • 6.3.3. Mexico Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Cancer Type
      • 6.3.3.2.3. By End-User

7. Europe Artificial Intelligence In Cancer Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Cancer Type
  • 7.2.3. By End-User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Cancer Type
      • 7.3.1.2.3. By End-User
  • 7.3.2. United Kingdom Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Cancer Type
      • 7.3.2.2.3. By End-User
  • 7.3.3. Italy Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Cancer Type
      • 7.3.3.2.3. By End-User
  • 7.3.4. France Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Cancer Type
      • 7.3.4.2.3. By End-User
  • 7.3.5. Spain Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Cancer Type
      • 7.3.5.2.3. By End-User

8. Asia-Pacific Artificial Intelligence In Cancer Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Cancer Type
  • 8.2.3. By End-User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Cancer Type
      • 8.3.1.2.3. By End-User
  • 8.3.2. India Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Cancer Type
      • 8.3.2.2.3. By End-User
  • 8.3.3. Japan Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Cancer Type
      • 8.3.3.2.3. By End-User
  • 8.3.4. South Korea Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Cancer Type
      • 8.3.4.2.3. By End-User
  • 8.3.5. Australia Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Cancer Type
      • 8.3.5.2.3. By End-User

9. South America Artificial Intelligence In Cancer Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Cancer Type
  • 9.2.3. By End-User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Cancer Type
      • 9.3.1.2.3. By End-User
  • 9.3.2. Argentina Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Cancer Type
      • 9.3.2.2.3. By End-User
  • 9.3.3. Colombia Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Cancer Type
      • 9.3.3.2.3. By End-User

10. Middle East and Africa Artificial Intelligence In Cancer Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Cancer Type
  • 10.2.3. By End-User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Cancer Type
      • 10.3.1.2.3. By End-User
  • 10.3.2. Saudi Arabia Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Cancer Type
      • 10.3.2.2.3. By End-User
  • 10.3.3. UAE Artificial Intelligence In Cancer Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Cancer Type
      • 10.3.3.2.3. By End-User

11. Market Dynamics

• 11.1. Driver
• 11.2. Challenges

12. Market Trends & Developments

13. Global Artificial Intelligence In Cancer Diagnostics Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Medial EarlySign
  • 14.1.1. Business Overview
  • 14.1.2. Cancer Type Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Key Personnel
  • 14.1.5. SWOT Analysis
• 14.2. Cancer Center.ai
• 14.3. Microsoft Corporation
• 14.4. Flatiron Health
• 14.5. Path AI
• 14.6. Therapixel
• 14.7. Tempus Labs, Inc.
• 14.8. Paige AI, Inc.
• 14.9. Kheiron Medical Technologies Limited
• 14.10. SkinVision

15. Strategic Recommendations

16. About Us & Disclaimer